Deals
Explore the dynamic landscape of pharma deals, mergers, acquisitions, and partnerships. Stay informed about strategic collaborations, licensing agreements, and investments shaping the industry. Get insights into the business side of pharmaceuticals and discover the key players driving innovation and growth.
Alexion Acquires Voyager’s Preclinical Capsid for Rare Neurological Disease After $1B Pfizer Transfer
Pfizer has transferred an AAV capsid designed for a rare neurological disease target to AstraZeneca’s rare disease subsidiary, Alexion, as ...
BMS Acquires Orum’s ADC ORM-6151 for AML and MDS Treatment
Bristol Myers Squibb (BMS) has made a significant move in the field of antibody-drug conjugates (ADCs) by acquiring Orum Therapeutics’ ...
AstraZeneca Buys 22% of Cellectis in Bold Cell, Gene Therapy Venture
AstraZeneca is making a significant move to collaborate with Cellectis, despite Cellectis discontinuing its multiple myeloma CAR-T program just five ...
Prelude Focuses on SMARCA in AbCellera Deal and Trims Its Portfolio by Dropping Two Phase 1 Candidates
Prelude Therapeutics is undergoing a strategic shift, significantly streamlining its clinical pipeline to focus on the promising potential of its ...
Moderna partners with CEPI to speed up vaccine development for future pandemics
Moderna is teaming up with the Coalition for Epidemic Preparedness Innovations (CEPI) to contribute to the 100 Days Mission, an ...
United Therapeutics acquires Miromatrix for bioengineered organ research
United Therapeutics is set to enhance its arsenal of organ manufacturing technologies with the acquisition of Miromatrix Medical, a developer ...
Merck Invests $169M in Selective PARP1 Drug, Intensifying Competition with AstraZeneca and Gilead
Merck KGaA is making a strategic move in the field of PARP inhibitors, investing a substantial 160 million euros ($169 ...
Accenture Song acquires ConcentricLife for $245M to boost ad capabilities
Accenture, known for its relentless pursuit of acquisitions, has returned to the deal table once again. The global services company, ...
Elektrofi lands $20M from Eli Lilly for subcutaneous drug partnership
Eli Lilly is collaborating with Elektrofi, a drug delivery specialist, to explore the potential of Elektrofi’s microparticle formulation technology in ...
AxoSim acquires Vyantās organoid tech for brain disorder research
AxoSim, a New Orleans-based drug discovery biotech, has successfully completed the acquisition of the neuroscience research assets from Vyant Bio’s ...
Roche’s $7B Investment Ignites Intense Competition with Merck in the Bowel Disease Market Amid TL1A Feeding Frenzy
Roche has made a substantial move by agreeing to pay Roivant and Pfizer $7.1 billion upfront for regional rights to ...
Merck Drops Two Cancer ADCs from Kelun Deal, Focuses on Daiichi Sankyo
Merck & Co. is refining its strategy in the realm of antibody-drug conjugates (ADCs). Shortly after a $4 billion acquisition ...
Merck and Daiichi join forces to develop novel cancer drugs in $22B deal
In a strategic move, Merck & Co. has solidified its position in the thriving field of antibody-drug conjugates (ADCs) through ...
PTC sells royalty rights of SMA drug Evrysdi to Royalty Pharma for $1.5B
As part of its cost-cutting efforts and in response to potential challenges in the European market, PTC Therapeutics is taking ...
Avania acquires two medtech CROs, broadens its global services and expertise
Avania, a medtech-focused Contract Research Organization (CRO) headquartered in the Netherlands, has extended its industry expertise through the strategic acquisitions ...
Lilly acquires European biotech Elahere, expands its ADC network and pipeline
Eli Lilly is actively expanding its involvement in the burgeoning field of antibody-drug conjugates (ADCs) in Europe. Following its recent ...
Basilea buys clinical-stage antifungal from Eisai, advances its anti-infective strategy
Basilea Pharmaceutica is making a strategic move to bolster its anti-infective pipeline, this time with a $2 million investment in ...
Siemens Healthineers and Qure.ai to deploy AI-powered chest X-ray screening for TB
Siemens Healthineers, in collaboration with Qure.ai and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, is intensifying efforts to ...
SpliceBio and Rocheās Spark Therapeutics team up for eye disease gene therapy
SpliceBio Initiates $216 Million Collaboration with Roche’s Gene Therapy Unit to Pave the Way for Innovative Inherited Retinal Disease Treatment ...
Gilead strikes $100 million deal with Assembly Bio for antiviral assets
Gilead Sciences is taking a unique approach to secure early access to Assembly Biosciences’ promising programs. Instead of an outright ...
Roche partners with Monte Rosa to develop molecular glue drugs for cancer
In a dynamic move, Roche has forged its second major agreement in the realm of molecular glue technology, this time ...
Concentra makes a bid to buy Rain Oncology, a struggling biotech with two cancer drugs
Concentra Biosciences, having weathered a failed acquisition of Atea Pharmaceuticals earlier this year, has now turned its attention to Rain ...
Novo Nordisk acquires Corvidia Therapeutics for $1.3B to compete with Bayerās Kerendia
Novo Nordisk, riding high on the success of its semaglutide sales, has taken a strategic leap by investing up to ...
Sotio inks $740M deal with Synaffix for ADC technology after lead drug setback
In a strategic move following the recent setback in its IL-15 asset trials, Sotio Biotech has embarked on an ambitious ...
Lonza to create over 100 jobs in Switzerland with new antibody filling line and expanded collaboration
In a series of recent strategic moves, Lonza, the prominent Swiss Contract Development and Manufacturing Organization (CDMO), is making headlines. ...
Eversana Intouch acquires Healthware Group to expand its biopharma services portfolio
Eversana Intouch, a prominent biopharma services company in the United States, is taking a significant step by acquiring its long-standing ...
Astria buys rights to Ichnosā eczema drug for $15M, joining crowded field of Amgen and Sanofi
Ichnos Sciences has secured a buyer for its OX40 eczema program, with Astria Therapeutics entering the scene by paying an ...
Haemonetics buys OpSens for $253M, a maker of smart TAVR guidewires
Boston-based medical device manufacturer Haemonetics is continuing its focus on expanding its portfolio of interventional cardiology devices with a strategic ...
Kanvas Bio emerges from Federationās demise with clinical-stage assets
In a strategic move, Kanvas Biosciences has seized the opportunity to acquire key assets from Federation Bio, a biotech company, ...
BMS invests more in Cellares to boost cell therapy manufacturing
Just six weeks following the initial announcement of a partnership between cell and gene therapy manufacturer Cellares and Bristol Myers ...
